Literature DB >> 8333775

Serum interleukin-1 alpha and soluble interleukin-2 receptor concentrations in cystic fibrosis.

P Greally1, M J Hussain, D Vergani, J F Price.   

Abstract

Interleukin (IL)-1 and IL-2 may participate in the systemic inflammatory response and hypergammaglobulinaemia observed in patients with cystic fibrosis. Thirty seven patients with cystic fibrosis were compared with 25 normal controls. High IgG and IgM concentrations were associated with more severe pulmonary disease. IL-1 alpha and soluble IL-2 receptor concentrations were higher in the cystic fibrosis group than in the controls and also correlated with concentrations of IgG and IgM. These results suggest that these cytokines may contribute to enhanced immunoglobulin synthesis and silent inflammatory activity in clinically stable patients with cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8333775      PMCID: PMC1029377          DOI: 10.1136/adc.68.6.785

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  5 in total

Review 1.  Interactions of Pseudomonas aeruginosa proteases with the cells of the immune system.

Authors:  A Kharazmi
Journal:  Antibiot Chemother (1971)       Date:  1989

2.  Raised serum soluble interleukin-2 receptor concentrations in cystic fibrosis patients with and without evidence of lung disease.

Authors:  E Dagli; J A Warner; C R Besley; J O Warner
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

3.  Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.

Authors:  H S Auerbach; M Williams; J A Kirkpatrick; H R Colten
Journal:  Lancet       Date:  1985-09-28       Impact factor: 79.321

4.  Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study.

Authors:  W B Wheeler; M Williams; W J Matthews; H R Colten
Journal:  J Pediatr       Date:  1984-05       Impact factor: 4.406

5.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

  5 in total
  11 in total

Review 1.  Role of corticosteroids in cystic fibrosis lung disease.

Authors:  I M Balfour-Lynn; R Dinwiddie
Journal:  J R Soc Med       Date:  1996       Impact factor: 5.344

2.  Liver transplantation for cirrhosis in cystic fibrosis.

Authors:  T Lamireau; S Martin; M Lallier; J E Marcotte; F Alvarez
Journal:  Can J Gastroenterol       Date:  2006-07       Impact factor: 3.522

3.  Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells.

Authors:  K Sugiyama; R Shirai; H Mukae; H Ishimoto; T Nagata; N Sakamoto; H Ishii; S Nakayama; K Yanagihara; Y Mizuta; S Kohno
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

4.  Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis.

Authors:  Basant A Abdulrahman; Arwa Abu Khweek; Anwari Akhter; Kyle Caution; Sheetal Kotrange; Dalia H A Abdelaziz; Christie Newland; Roberto Rosales-Reyes; Benjamin Kopp; Karen McCoy; Richard Montione; Larry S Schlesinger; Mikhail A Gavrilin; Mark D Wewers; Miguel A Valvano; Amal O Amer
Journal:  Autophagy       Date:  2011-11-01       Impact factor: 16.016

Review 5.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

6.  Reduced pancreatic insulin release and reduced peripheral insulin sensitivity contribute to hyperglycaemia in cystic fibrosis.

Authors:  R W Holl; E Heinze; A Wolf; M Rank; W M Teller
Journal:  Eur J Pediatr       Date:  1995-05       Impact factor: 3.183

Review 7.  Sputum biomarkers of inflammation in cystic fibrosis lung disease.

Authors:  Scott D Sagel; James F Chmiel; Michael W Konstan
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

8.  Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone.

Authors:  P Greally; M J Hussain; D Vergani; J F Price
Journal:  Arch Dis Child       Date:  1994-07       Impact factor: 3.791

9.  Potential of anti-inflammatory treatment for cystic fibrosis lung disease.

Authors:  Jennifer L Taylor-Cousar; Kelsey A Von Kessel; Robert Young; David P Nichols
Journal:  J Inflamm Res       Date:  2010-08-10

10.  Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes.

Authors:  Veerle Reynders; Stefan Loitsch; Constanze Steinhauer; Thomas Wagner; Dieter Steinhilber; Joachim Bargon
Journal:  Respir Res       Date:  2006-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.